Larimer and colleagues have shown a high level of infiltration of T-cells during anti-CTLA4 treatment by targeting the T-cell surface glycoprotein CD3 in colon cancer xenograft models using a murine 89Zr-labelled anti-CD3 [18]. This evidence concerns the gene CTLA4 and malignant colon neoplasm.